Barriers to Prescribing Effective Recurrent CDI Therapies

There may be barriers, including insurance denials, to using products that are effective for recurrent ...

JUNE 3, 2025

C. diff in 2024: New Treatments For a Stubborn Problem

The key to understanding and effectively treating Clostridioides difficile infection is noting its two phases: the ...

APRIL 19, 2024

Microbiota Treatments Safe, Effective for Recurrent CDI

Use of the new fecal microbiota products following antibiotics in the treatment of recurrent Clostridioides ...

APRIL 19, 2024

Combating Inappropriate Abx Prescribing at Hospital Discharge

Inappropriate oral antibiotic prescribing at hospital discharge remains common, said experts at the IDWeek 2023 ...

DECEMBER 4, 2023

FDA Approves Rebyota, the First Live Biotherapeutic Fecal Microbiota Product in the U.S.

RBX2660 (Rebyota, Ferring) is approved by the FDA for the prevention of recurrent Clostridioides difficile ...

DECEMBER 3, 2022

Investigational Biotherapeutic Effective Against C. difficile Up to 24 Months

The investigational microbiota-based live biotherapeutic, which was endorsed by the FDA's Vaccines and Related ...

OCTOBER 11, 2022

C. diff Testing Shouldn’t Be Based on Lab Test Alone

 CDI should not be based on a laboratory test alone but should take into consideration the patient’s ...

JANUARY 30, 2019